JARBINA

Allergan Finance, LLC

Application Filed: 2017-07-10
Trademark Application Details
Trademark Logo JARBINA
732
Live/Pending
THIRD EXTENSION - GRANTED
Research OneLook Acronym Finder
Serial Number87521989
Mark Drawing Code4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Law Office AssignedN10
Employee NameEVANKO, PATRICIA MALES

Timeline

2017-07-10Application Filed
2017-12-05Published for Opposition
2018-01-30Location: INTENT TO USE SECTION
2019-06-14Status: Live/Pending
2019-07-08Transaction Date

Trademark Applicants & Owners

Owner: Allergan Finance, LLC
Address400 Interpace Parkway Parsippany NV 07054
Legal Entity TypeLimited Liability Company
Legal Entity StateNV

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

SUSAN J. HINCHEY
ALLERGAN, INC.
2525 DUPONT DRIVE
IRVINE, CA 92612

Good, Services, and Codes

International Codes:5
U.S. Codes:006,018,044,046,051,052
Type CodeType
GS0051Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical blood therapy preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and body

Trademark Filing History

DescriptionDateEvent Coding
NEW APPLICATION ENTERED IN TRAM2017-07-131 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM2017-07-152 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER2017-10-053 DOCK D:Assigned to Examiner
EXAMINERS AMENDMENT -WRITTEN2017-10-134 CNEA R:Renewal
EXAMINERS AMENDMENT E-MAILED2017-10-135 GNEA F:First Action
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED2017-10-136 GNEN O:Outgoing Correspondence
EXAMINER'S AMENDMENT ENTERED2017-10-137 XAEC I:Incoming Correspondence
APPROVED FOR PUB - PRINCIPAL REGISTER2017-10-138 CNSA P:
ASSIGNED TO LIE2017-10-309 ALIE A:Allowance for Publication
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED2017-11-1510 NONP E:E-Mail
PUBLISHED FOR OPPOSITION2017-12-0511 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED2017-12-0512 NPUB E:E-Mail
NOA E-MAILED - SOU REQUIRED FROM APPLICANT2018-01-3013 NOAM E:E-Mail
TEAS EXTENSION RECEIVED2018-07-1914 EEXT I:Incoming Correspondence
EXTENSION 1 FILED2018-07-1915 EXT1 S:
EXTENSION 1 GRANTED2018-07-1916 EX1G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2018-07-2117 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2019-01-2318 EEXT I:Incoming Correspondence
EXTENSION 2 FILED2019-01-2319 EXT2 S:
EXTENSION 2 GRANTED2019-01-2320 EX2G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2019-01-2521 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2019-06-1422 EEXT I:Incoming Correspondence
EXTENSION 3 FILED2019-06-1423 EXT3 S:
EXTENSION 3 GRANTED2019-06-1424 EX3G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2019-06-1825 EXRA E:E-Mail
ASSIGNED TO EXAMINER2019-07-0826 DOCK D:Assigned to Examiner
TEAS EXTENSION RECEIVED2020-01-2427 EEXT I:Incoming Correspondence
EXTENSION 4 FILED2020-01-2428 EXT4 S:
EXTENSION 4 GRANTED2020-01-2429 EX4G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2020-01-2830 EXRA E:E-Mail
TEAS EXTENSION RECEIVED2020-07-2431 EEXT I:Incoming Correspondence
CASE ASSIGNED TO INTENT TO USE PARALEGAL2020-08-1232 AITU A:Allowance for Publication
EXTENSION 5 FILED2020-07-2433 EXT5 S:
EXTENSION 5 GRANTED2020-08-1234 EX5G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED2020-08-1335 EXRA E:E-Mail
ABANDONMENT - NO USE STATEMENT FILED2021-03-0836 ABN6 S:
ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED2021-03-0837 MAB6 E:E-Mail

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed